DeepMed Research

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)
Drug: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)

First Posted Date: 2011-10-25

Last Posted Date: 2013-02-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT01459094

A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-39439335

First Posted Date: 2011-10-18

Last Posted Date: 2013-01-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 43

Registration Number: NCT01454245

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

Phase 1

Completed

Conditions: Healthy Male Volunteer

Interventions: Drug: JNJ-38518168 (30 mg)
Drug: JNJ-38518168 (10 mg)
Drug: JNJ-38518168 (3 mg)
Drug: Placebo
Drug: Midazolam and JNJ-38518168

First Posted Date: 2011-09-28

Last Posted Date: 2013-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 94

Registration Number: NCT01442532

A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease

Early Phase 1

Completed

Conditions: Healthy
Alzheimer Disease

Interventions: Procedure: Standard frequent CSR sampling procedure with 800 mg ibuprofen
Procedure: Alternate frequency CSR sampling procedure
Procedure: Standard CSR sampling procedure
Procedure: Alternative lower frequency CSR sampling procedure

First Posted Date: 2011-09-19

Last Posted Date: 2014-03-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 5

Registration Number: NCT01436188

A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: T2-18C3 therapeutic antibody

First Posted Date: 2011-09-01

Last Posted Date: 2021-02-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 7

Registration Number: NCT01427699

Locations: 🇨🇭
University Hospital of Basel, Basel, Switzerland

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Phase 2

Completed

Conditions: Multicentric Castleman's Disease

Interventions: Drug: Siltuximab

First Posted Date: 2011-07-22

Last Posted Date: 2018-05-22

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 60

Registration Number: NCT01400503

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rivaroxaban
Drug: Warfarin
Drug: Vitamin K

First Posted Date: 2011-07-22

Last Posted Date: 2017-01-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 46

Registration Number: NCT01400646

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Phase 2

Completed

Conditions: Primary Biliary Cirrhosis

Interventions: Drug: ustekinumab 45 mg
Drug: ustekinumab 90 mg
Drug: Placebo
Drug: ustekinumab 180 mg

First Posted Date: 2011-07-08

Last Posted Date: 2016-06-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 20

Registration Number: NCT01389973

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: RA-18C3

First Posted Date: 2011-06-29

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 8

Registration Number: NCT01384630

Locations: 🇺🇸
West Kentucky Dermatology, Owensboro, Kentucky, United States
🇺🇸
Westlake Dermatology, Austin, Texas, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Canagliflozin 100mg
Drug: Placebo
Drug: Canagliflozin 300mg
Drug: Metformin
Drug: Sulphonylurea

First Posted Date: 2011-06-27

Last Posted Date: 2014-05-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 678

Registration Number: NCT01381900

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy